Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

BMS-833923

Generic Name: BMS-833923

Drug Type: Small Molecule

Chemical Formula: C_₃₀H_₂₇N_₅O

CAS Number: 1059734-66-5

Unique Ingredient Identifier: 41J7ZJ239R

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Study of BMS-833923 in Two Specific Patients With Basal Cell Nevus Syndrome

Not Applicable

Completed

Posted: 2014/03/31

Sponsor:University Health Ne...

ID:NCT02100371

Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects With Solid Tumors

Phase 1

Completed

Posted: 2011/08/10

Sponsor:Bristol-Myers Squibb

ID:NCT01413906

Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)

Phase 2

Terminated

Posted: 2011/05/23

Sponsor:Bristol-Myers Squibb

ID:NCT01357655

Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)

Phase 1

Completed

Posted: 2010/10/11

Sponsor:Bristol-Myers Squibb

ID:NCT01218477

A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer

Phase 1

Completed

Posted: 2009/06/25

Sponsor:Bristol-Myers Squibb

ID:NCT00927875

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy